In today’s session Alexion Pharmaceuticals, Inc. (ALXN) recorded an unusually high (375) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious ALXN decrease. With 375 contracts traded and 364 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: ALXN161216P00120000 closed last at: $3.5 or 6.1% up. It is down 12.86% since April 5, 2016 and is downtrending. It has underperformed by 14.81% the S&P500.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage
Out of 20 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 15 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 75% are positive. $257 is the highest target while $82 is the lowest. The $177.47 average target is 40.43% above today’s ($126.38) stock price. Alexion Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 27, 2015 according to StockzIntelligence Inc. As per Monday, September 14, the company rating was downgraded by Barclays Capital. The firm has “Mkt Perform” rating by FBR Capital given on Friday, October 28. The company was maintained on Friday, July 31 by Brean Capital. Raymond James initiated Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, September 1 with “Strong Buy” rating. The firm has “Market Perform” rating given on Thursday, April 7 by BMO Capital Markets. The firm has “Overweight” rating given on Monday, July 27 by JP Morgan. Wedbush initiated Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Friday, September 23. Wedbush has “Neutral” rating and $132 price target. Morgan Stanley maintained the stock with “Overweight” rating in Tuesday, June 7 report. The firm has “Overweight” rating given on Friday, October 2 by Morgan Stanley. The stock has “Outperform” rating given by Leerink Swann on Monday, September 26.
According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.”
Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.42, from 0.77 in 2016Q1. The ratio improved, as 51 funds sold all Alexion Pharmaceuticals, Inc. shares owned while 155 reduced positions. 58 funds bought stakes while 188 increased positions. They now own 212.84 million shares or 4.67% less from 223.26 million shares in 2016Q1.
Bnp Paribas Arbitrage Sa reported 129,063 shares or 0.07% of all its holdings. Keybank Association Oh has 5,504 shares for 0% of their US portfolio. The Tennessee-based Ftb Advsrs has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Baker Bros Advisors Limited Partnership accumulated 8.01% or 6.54 million shares. Arizona State Retirement Systems has invested 0.09% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Deere accumulated 0.1% or 15,471 shares. Quantitative Systematic Strategies Lc holds 0.52% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 9,723 shares. The Kentucky-based D Scott Neal Inc has invested 0.21% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Grp One Trading Ltd Partnership has 1,300 shares for 0% of their US portfolio. Temasek (Private) Ltd has 1.12% invested in the company for 1.23 million shares. Hsbc Pcl accumulated 100,774 shares or 0.03% of the stock. Tokio Marine Asset has 7,019 shares for 0.08% of their US portfolio. Raymond James Financial Service Advsrs accumulated 152,683 shares or 0.17% of the stock. First Republic Inv Mngmt, a California-based fund reported 11,245 shares. Hightower Ltd Llc has invested 0.03% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Insider Transactions: Since May 13, 2016, the stock had 0 buys, and 19 selling transactions for $4.73 million net activity. Shares for $124,591 were sold by Moriarty John B on Monday, June 13. Shares for $37,988 were sold by Sinha Vikas on Monday, August 8. 1,634 shares were sold by BELL LEONARD, worth $221,078. Carmichael Clare sold $127,760 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, August 30. O’Neill Julie sold $82,089 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, September 2. Thiel Carsten sold $551,364 worth of stock. On Friday, May 13 Wagner Heidi L sold $7,348 worth of the stock or 53 shares.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $27.55 billion. The Firm is focused on the development and commercialization of life-transforming therapeutic products. It has a 77.67 P/E ratio. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment.
ALXN Company Profile
Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.